Breast Cancer Research and Treatment

, Volume 135, Issue 3, pp 693–703

Is there ‘progression through grade’ in ductal invasive breast cancer?

  • Barbara Schymik
  • Horst Buerger
  • Annika Krämer
  • Ulli Voss
  • Petra van der Groep
  • Wolfgang Meinerz
  • Paul J. van Diest
  • Eberhard Korsching
Preclinical Study

Abstract

Recent molecular data pointed towards the possibility of a stepwise dedifferentiation in a subgroup of invasive breast cancer (BC) cases. It was hypothesized that oestrogen receptor positive (ER+) grade 3 (G3) ductal invasive BCs are the end stage of a dedifferentiation process of luminal BC. A progression of luminal A towards luminal B BCs associated with a ‘progression through grade’ and an increased cell proliferation seemed the obvious explanation. In order to verify this hypothesis on a morphological and immunohistochemical level, we investigated 865 invasive BC cases. All cases were reviewed for the presence of intratumoural heterogeneity in grade of the invasive cancer and the presence of associated ductal carcinoma in situ (DCIS). With the use of tissue microarrays, the molecular subtype was determined and correlated with clinico-pathological features. In addition, all cases were stained for p21, p27, Ki-67, Cyclin D1, bcl-2, p53, and p16 and the results subjected to a biomathematical dependency analysis. The frequency of ER-positivity decreased with tumour size. The frequency of luminal A BC decreased as well, whereas the number of luminal B BCs remained constant. A gradual increase of the frequency of basal-like, HER2-driven and non-expressor BCs with tumour size was seen. In only 1 out of 865 BC cases, both a G1 and a G3 invasive cancer component was seen within the same BC. In two cases, a ductal invasive G1 carcinoma was associated with a poorly-differentiated DCIS. The frequency of columnar cell lesions was evenly distributed over ER+ and ER− ductal invasive G3 carcinomas. The biomathematical analysis gave striking hints against an obligate progression of BC trough grade. In conclusion, our results show that a morphological recognizable striking ‘progression through grade’ at least in its extreme form from G1 towards G3 is a very rare event in the natural course of invasive BC, including luminal BC.

Keywords

Breast cancer Breast cancer progression Estrogen receptor 

References

  1. 1.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRefGoogle Scholar
  2. 2.
    Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC (1999) The natural history of breast carcinoma: What have we learned from screening? Cancer 86(3):449–462PubMedCrossRefGoogle Scholar
  3. 3.
    Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H (2008) Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 61(5):553–560PubMedCrossRefGoogle Scholar
  4. 4.
    Vos CB, ter Haar HN, Rosenberg C, Peterse JL, Cleton JA, Cornelisse CJ, van-de Vijver VM (2000) Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer 81(8):1410–1418CrossRefGoogle Scholar
  5. 5.
    Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP (1999) Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat 58(2):163–169PubMedCrossRefGoogle Scholar
  6. 6.
    Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, Van Der WE (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93(4):309–314PubMedCrossRefGoogle Scholar
  7. 7.
    Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189(4):521–526PubMedCrossRefGoogle Scholar
  8. 8.
    Korsching E, Packeisen J, Helms MW, Kersting C, Voss R, van Diest PJ, Brandt B, Van Der WE, Boecker W, Burger H (2004) Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer 90(7):1422–1428PubMedCrossRefGoogle Scholar
  9. 9.
    Natrajan R, Lambros MB, Geyer FC, Marchio C, Tan DS, Vatcheva R, Shiu KK, Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, Reis-Filho JS (2009) Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 48(4):351–365PubMedCrossRefGoogle Scholar
  10. 10.
    Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Investig 82(11):1525–1533PubMedGoogle Scholar
  11. 11.
    Tavassoli FA, Devilee P (eds) (2003) Intraductal proliferative lesions. In: World health organization. Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, p 63–73Google Scholar
  12. 12.
    Schnitt SJ, Collins LC (2005) Columnar cell lesions and flat epithelial atypia of the breast. Semin Breast Dis 8:100–111 Google Scholar
  13. 13.
    Packeisen J, Korsching E, Herbst H, Boecker W, Buerger H (2003) Demystified…tissue microarray technology. Mol Pathol 56(4):198–204PubMedCrossRefGoogle Scholar
  14. 14.
    Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, De Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ (2012) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 25(3):398–404Google Scholar
  15. 15.
    Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W (1999) Comparative genomic hybridization of ductal carcinoma in situ of the breast- evidence of multiple genetic pathways. J Pathol 187(4):396–402PubMedCrossRefGoogle Scholar
  16. 16.
    van Deurzen CH, Lee AH, Gill MS, Menke-Pluijmers MB, Jager A, Ellis IO, Rakha EA (2011) Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation? J Pathol 224(4):434–437PubMedCrossRefGoogle Scholar
  17. 17.
    Tabar L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, Chiu SY, Chen SL, Fann JC, Rosell J, Fohlin H, Smith RA, Duffy SW (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260(3):658–663PubMedCrossRefGoogle Scholar
  18. 18.
    Roylance R, Gorman P, Papior T, Wan YL, Ives M, Watson JE, Collins C, Wortham N, Langford C, Fiegler H, Carter N, Gillett C, Sasieni P, Pinder S, Hanby A, Tomlinson I (2006) A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene 25(49):6544–6553PubMedCrossRefGoogle Scholar
  19. 19.
    Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216(4):399–407PubMedCrossRefGoogle Scholar
  20. 20.
    Boulos FI, Dupont WD, Schuyler PA, Sanders ME, Page DL, Fedda FA, Simpson JF (2012) Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions: evidence against a precursor role. Cancer 118(9):2372–2377Google Scholar
  21. 21.
    Collins LC, Achacoso NA, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, Alshak NS, Puligandla B, Brodsky GL, Schnitt SJ, Habel LA (2007) Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod Pathol 20(11):1149–1155PubMedCrossRefGoogle Scholar
  22. 22.
    Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, Hanby A, Pinder SE, Lee AH, Humphreys S, Ellis IO, Lakhani SR (2005) Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 29(6):734–746PubMedCrossRefGoogle Scholar
  23. 23.
    Aroner SA, Collins LC, Schnitt SJ, Connolly JL, Colditz GA, Tamimi RM (2010) Columnar cell lesions and subsequent breast cancer risk: a nested case–control study. Breast Cancer Res 12(4):R61PubMedCrossRefGoogle Scholar
  24. 24.
    Boulos FI, Dupont WD, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, Page DL (2008) Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case–control study. Cancer 113(9):2415–2421PubMedCrossRefGoogle Scholar
  25. 25.
    Korsching E, Packeisen J, Liedtke C, Hungermann D, Wulfing P, van Diest PJ, Brandt B, Boecker W, Buerger H (2005) The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206(4):451–457PubMedCrossRefGoogle Scholar
  26. 26.
    Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19(5):617–621PubMedCrossRefGoogle Scholar
  27. 27.
    Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38(2):197–204PubMedCrossRefGoogle Scholar
  28. 28.
    Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van-de Vijver VM, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11(3):167–180PubMedGoogle Scholar
  29. 29.
    Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67PubMedCrossRefGoogle Scholar
  30. 30.
    Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23(9):974–979PubMedCrossRefGoogle Scholar
  31. 31.
    Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O’Connell P, Tsimelzon A, Medina D (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14(2):370–378PubMedCrossRefGoogle Scholar
  32. 32.
    Buerger H, Simon R, Schaefer KL, Diallo R, Littmann R, Poremba C, van Diest PJ, Dockhorn-Dworniczak B, Boecker W (2000) Genetic relationship of lobular carcinoma in situ, ductal carcinoma in situ and associated invasive carcinoma of the breast. Mol Pathol 53(3):118–121PubMedCrossRefGoogle Scholar
  33. 33.
    Boecker W, Buerger H, Schmitz K, Ellis IO, van Diest PJ, Sinn HP, Geradts J, Poremba C, Herbst H (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 195(4):415–421PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Barbara Schymik
    • 1
    • 2
  • Horst Buerger
    • 2
    • 3
    • 4
  • Annika Krämer
    • 3
  • Ulli Voss
    • 3
  • Petra van der Groep
    • 4
  • Wolfgang Meinerz
    • 1
    • 2
  • Paul J. van Diest
    • 4
  • Eberhard Korsching
    • 5
  1. 1.Clinics of GynecologySt. Vincenz HospitalPaderbornGermany
  2. 2.Cooperative Breast Center PaderbornPaderbornGermany
  3. 3.Institute of PathologyPaderbornGermany
  4. 4.Department of PathologyUniversity of UtrechtUtrechtThe Netherlands
  5. 5.Institute of BioinformaticsUniversity Hospital of Muenster, University of MuensterMuensterGermany

Personalised recommendations